<DOC>
	<DOCNO>NCT01112826</DOCNO>
	<brief_summary>The primary objective study compare disease-free survival ( DFS ) patient triple negative breast cancer randomise treatment standard adjuvant chemotherapy alone standard adjuvant chemotherapy follow 1 year Capecitabine ( Xeloda ) metronomic therapy .</brief_summary>
	<brief_title>Efficacy Capecitabine Metronomic Chemotherapy Triple-negative Breast Cancer</brief_title>
	<detailed_description>Triple negative breast cancer ( TNBC ) aggressive disease without tumor-specific treatment option . Patients triple-negative disease increase likelihood distant recurrence death within 5 year diagnosis . Median time distant recurrence significantly shorter.This study evaluate efficacy safety addition Capecitabine ( Xeloda ) standard adjuvant therapy patient triple negative breast cancer . Patients randomize receive either standard chemotherapy ( accord NCCN guideline ) , standard chemotherapy follow 1 year metronomic Capecitabine ( 650mg/m2 , twice every day ) . The anticipated time study treatment 6-12 month , target sample size 424 individuals.Disease-free Survival ( DFS ) primary end point .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Patients must &gt; =18 year age ; The patient must Operable primary invasive breast cancer ; Definitive locoregional surgery must complete ; Primary tumor centrally confirm triple negative ; Operable nodepositive ( nodenegative tumor diameter â‰¥ 0.5cm ) ; Chest , abdominal , bone imaging perform 3 month prior randomization must reveal presence distant spread ; There normal organ function , include bone marrow function , renal function , liver function , cardiac function ; All patient must sign date informed consent form . Patients bilateral breast cancer , inflammatory carcinoma ; Patients positive supraclavicular internal mammary lymph node ; Previous breast cancer history ; Any previous malignancy exception carcinoma cervix , squamous carcinoma skin , basal cell carcinoma skin ; Pregnant breastfeed woman ; Women unwilling agree use effective nonhormonal method contraception treatment period Xeloda ; Any sex hormonal therapy ; Malabsorption syndrome .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>triple-negative breast cancer</keyword>
	<keyword>metronomic chemotherapy</keyword>
	<keyword>capecitabine ( xeloda )</keyword>
</DOC>